AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
AIM ImmunoTech announced that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with Imfinzi for metastatic pancreatic cancer. The trial's primary endpoint analysis is expected to start in December 2026 with topline results anticipated in Q1 2027. The company aims to use explor…